Comparative Pharmacology
Head-to-head clinical analysis: NOLVADEX versus TOREMIFENE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOLVADEX versus TOREMIFENE CITRATE.
NOLVADEX vs TOREMIFENE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.
Nonsteroidal estrogen receptor antagonist; binds to estrogen receptors (ER) with high affinity, competitively inhibiting estrogen binding and exerting antiestrogenic effects. Also possesses weak estrogenic agonist activity.
20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.
60 mg orally once daily
None Documented
None Documented
Tamoxifen: 5-7 days (terminal). N-desmethyltamoxifen (active metabolite): 14 days. Steady-state achieved in 3-4 weeks.
About 5 days for the parent compound; clinical context: steady-state achieved in ~4 weeks
Primarily fecal (65%) as conjugates; renal excretion accounts for approximately 25% as metabolites and <0.5% as unchanged drug. Biliary elimination contributes 10%.
Primarily fecal (biliary excretion) as metabolites; approximately 10% renal
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator